Summit looks to repeat ivo's Chinese success
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
ELCC 2025 – subQ Keytruda heads towards approval
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
ELCC 2025 – J&J takes it to Tagrisso
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
